Skip to main content
Autobound logo
Biogen8-K: Acquisition completed

Biogen completes acquisition of Apellis Pharmaceuticals, disclosed on May 14, 2026.

Read at SEC EDGAR

What happened

The integration of Apellis Pharmaceuticals will require Biogen to consolidate systems, processes, and personnel across finance, IT, HR, and R&D.

Source

SEC EDGARJun 10, 2026

Current report (Form 8-K)

Biogen 8-K

Filing excerpt

On May 14, 2026, Biogen Inc., a Delaware corporation (“Biogen”), filed a Current Report on Form 8-K (the “Original Report”) with the U.S. Securities and Exchange Commission.

sec.gov/Archives/edgar/data/875045/000095015726000699/form8-ka.htmRead the full source

Other signals in this filing (1)

Extracted by Autobound

From the Signal API record
Signal
8-K: Acquisition completed

What this signalsIntegration work after a deal often opens needs for new systems and services.

Form
8-K
Filed
Jun 10, 2026

More from Biogen

Company page →

More 8-K signals at other companies

The full record

From the Signal API record

Details

CIK
875045
Accession number
0000950157-26-000699
Timeframe
Current quarter
Filing year
2026
Why it matters
Active integration needs
Signal category
Strategic

Extraction

Confidence
High
Relevance
90%
Sentiment
Neutral
Detected
Jun 16, 2026
signal_type
sec-8k
signal_subtype
acquisitionCompleted

Use this data

Get every 8-K signal for Biogen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/9aabced7-7ca9-40c6-ba59-c63fc82fb8ed returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.

{
  "signal_id": "9aabced7-7ca9-40c6-ba59-c63fc82fb8ed",
  "signal_type": "sec-8k",
  "signal_subtype": "acquisitionCompleted",
  "detected_at": "2026-06-16T09:36:57.776+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "detail": "The integration of Apellis Pharmaceuticals will require Biogen to consolidate systems, processes, and personnel across finance, IT, HR, and R&D. This creates immediate opportunities for vendors specializing in post-merger integration, platform consolidation, and change management to address operational complexities.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "Biogen completes acquisition of Apellis Pharmaceuticals, disclosed on May 14, 2026.",
    "excerpts": "On May 14, 2026, Biogen Inc., a Delaware corporation (“Biogen”), filed a Current Report on Form 8-K (the “Original Report”) with the U.S. Securities and Exchange Commission.",
    "relevance": 0.9,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/875045/000095015726000699/form8-ka.htm",
    "filing_date": "2026-06-10",
    "filing_year": 2026,
    "sales_relevance": "Active integration needs",
    "signal_category": "strategic"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.